VLKIM
REGN icon

Van Lanschot Kempen Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Van Lanschot Kempen Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-116
Closed -$89.5K – 260
2025
Q4 		$89.5K Sell
116
-6,202
-98% -$4.21M ﹤0.01% 242
2025
Q3 		$3.55M Sell
6,318
-776
-11% -$439K 0.03% 212
2025
Q2 		$3.72M Buy
7,094
+1,627
+30% +$908K 0.04% 210
2025
Q1 		$3.47M Buy
5,467
+149
+3% +$102K 0.04% 198
2024
Q4 		$3.79M Sell
5,318
-954
-15% -$801K 0.04% 194
2024
Q3 		$6.59M Sell
6,272
-1,313
-17% -$1.46M 0.07% 152
2024
Q2 		$7.97M Buy
7,585
+958
+14% +$929K 0.09% 142
2024
Q1 		$6.38M Buy
6,627
+1,520
+30% +$1.45M 0.08% 148
2023
Q4 		$4.49M Buy
5,107
+272
+6% +$224K 0.06% 152
2023
Q3 		$3.98M Buy
4,835
+403
+9% +$317K 0.07% 132
2023
Q2 		$3.18M Buy
4,432
+136
+3% +$105K 0.06% 146
2023
Q1 		$3.53M Buy
4,296
+240
+6% +$181K 0.07% 141
2022
Q4 		$2.93M Buy
4,056
+410
+11% +$303K 0.09% 142
2022
Q3 		$2.51M Sell
3,646
-568
-13% -$357K 0.1% 132
2022
Q2 		$2.49M Buy
4,214
+170
+4% +$111K 0.09% 132
2022
Q1 		$2.82M Buy
+4,044
New +$2.56M 0.09% 129

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Van Lanschot Kempen Investment Management's REGN Position: Q1 2026 in Review

Van Lanschot Kempen Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 116 shares — an estimated $89.5K sold.

Van Lanschot Kempen Investment Management first reported a position in REGN in Q1 2022 and held it in 16 quarters. The position peaked at $7.97M in Q2 2024. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Van Lanschot Kempen Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Van Lanschot Kempen Investment Management sold 116 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $89.5K.
  • Van Lanschot Kempen Investment Management first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Van Lanschot Kempen Investment Management's Regeneron Pharmaceuticals position peaked at $7.97M in Q2 2024.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Van Lanschot Kempen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.